Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Plant-based vegetarian and vegan diets may have the lowest carbon footprint in the United States, but new data analysis shows fish-based pescatarian diets are the best.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer
2.
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
3.
Cancerous breast tissue glows in new AI-enhanced MRI images
4.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
5.
enhancing survivors of brain tumors' quality of life.
1.
Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025
2.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
3.
How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?
4.
The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment
5.
From Birthmarks to Tumors: The Science Behind Infantile Hemangioma
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge